GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VBI Vaccines Inc (OTCPK:VBIVQ) » Definitions » Cyclically Adjusted Price-to-FCF

VBIVQ (VBI Vaccines) Cyclically Adjusted Price-to-FCF : (As of Dec. 13, 2024)


View and export this data going back to 2016. Start your Free Trial

What is VBI Vaccines Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


VBI Vaccines Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for VBI Vaccines's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VBI Vaccines Cyclically Adjusted Price-to-FCF Chart

VBI Vaccines Annual Data
Trend Mar14 Mar15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

VBI Vaccines Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of VBI Vaccines's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, VBI Vaccines's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VBI Vaccines's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VBI Vaccines's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where VBI Vaccines's Cyclically Adjusted Price-to-FCF falls into.



VBI Vaccines Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

VBI Vaccines's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, VBI Vaccines's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.485/131.7762*131.7762
=-0.485

Current CPI (Mar. 2024) = 131.7762.

VBI Vaccines Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -4.713 100.560 -6.176
201409 -4.072 100.428 -5.343
201412 -1.545 99.070 -2.055
201503 -5.010 99.621 -6.627
201506 -2.891 100.684 -3.784
201509 0.000 100.392 0.000
201512 -6.119 99.792 -8.080
201603 -2.384 100.470 -3.127
201606 -6.099 101.688 -7.904
201609 -3.121 101.861 -4.038
201612 -6.593 101.863 -8.529
201703 -6.379 102.862 -8.172
201706 -6.021 103.349 -7.677
201709 -4.371 104.136 -5.531
201712 -5.120 104.011 -6.487
201803 -4.485 105.290 -5.613
201806 -7.923 106.317 -9.820
201809 -7.007 106.507 -8.669
201812 -4.267 105.998 -5.305
201903 -4.899 107.251 -6.019
201906 -4.081 108.070 -4.976
201909 -4.103 108.329 -4.991
201912 -1.462 108.420 -1.777
202003 -1.309 108.902 -1.584
202006 -1.099 108.767 -1.331
202009 -1.956 109.815 -2.347
202012 -2.103 109.897 -2.522
202103 -0.860 111.754 -1.014
202106 -1.308 114.631 -1.504
202109 -0.521 115.734 -0.593
202112 -2.227 117.630 -2.495
202203 -2.372 121.301 -2.577
202206 -2.152 125.017 -2.268
202209 -2.158 125.227 -2.271
202212 -2.381 125.222 -2.506
202303 -2.578 127.348 -2.668
202306 -2.237 128.729 -2.290
202309 -0.381 129.860 -0.387
202312 -0.511 129.419 -0.520
202403 -0.485 131.776 -0.485

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


VBI Vaccines  (OTCPK:VBIVQ) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


VBI Vaccines Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of VBI Vaccines's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


VBI Vaccines Business Description

Industry
Traded in Other Exchanges
N/A
Address
160 Second Street, Floor 3, Cambridge, MA, USA, 02142
VBI Vaccines Inc is a commercial-stage, the biopharmaceutical company which is engaged in developing next-generation vaccines to address unmet needs in infectious disease and immuno-oncology. The company manufactures Sci-B-Vac product which is a hepatitis B (HBV) vaccine for adults, children, and newborns. Its products include Virus-Like Particle which is vaccine platform which allows for the design of enveloped virus-like particle vaccines that closely mimic the target viruses. The company operates through the single segment being Developing vaccines to address unmet needs in infectious disease and immuno-oncology.
Executives
Steven Gillis director 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Vaughn B Himes director C/O SEATTLE GENETICS, INC., 21823 30TH DRIVE SE, BOTHELL WA 98021
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
John Robert Dillman officer: Chief Commercial Officer C/O VBI VACCINES INC., 160 SECOND STREET, FLOOR 3, CAMBRIDGE MA 02142
Nell Beattie officer: Director, Corp Development/IR 222 THIRD STREET, SUITE 2241, CAMBRIDGE MA 02142
Linda Bain director C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Damian Braga director 222 THIRD STREET, SUITE 2241, CAMBRIDGE MA 02142
Francisco Diaz-mitoma officer: Chief Medical Officer 222 THIRD STREET, SUITE 2241, CAMBRIDGE MA 02142
Christopher Mcnulty officer: CFO and Head of BD C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Jeff Baxter director, officer: President and CEO C/O VBI VACCINES INC.,, 222 THIRD STREET, STE 2241, CAMBRIDGE MA 02142
Joanne Cordeiro director 171 SWANTON STREET, UNIT 48, WINCHESTER MA 01890
Blaine H. Mckee director C/O HART, 84 OCTOBER HILL ROAD, SUITE 11, HOLLISTON MA 01746
Tomer Kariv director C/O ARNO THERAPEUTICS, INC., 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003